Opendata, web and dolomites

HEXKIN

Healing Exosomes for sKIN

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HEXKIN project word cloud

Explore the words cloud of the HEXKIN project. It provides you a very rough idea of what is the project "HEXKIN" about.

demand    human    capacity    accomplishment    secreted    hard    believe    emerged    restricted    valley    validation    competition    secure    skin    heal    classic    limited    active    clinical    chronic    capital    70    humans    currently    commercialisation    million    burden    fast    healthcare    trials    severe    strategies    overcome    market    place    close    globally    cell    stimulation    safety    position    treatment    therapies    clinically    ideal    instrument    constitute    revenues    sme    considering    spin    tool    models    efficacy    ucb    healing    segment    standard    opportunity    validate    umbilical    stages    wound    wounds    reveal    reported    swift    accelerate    vehicle    ulcers    company    competitive    entrance    maintaining    patients    generate    engraftment    blood    nevertheless    commercialization    death    global    cells    improvements    diabetic    promotion    successful    exo    vascularisation    solutions    business    survival    assist    suffering    exogenus    biocompatibility    cord    care    gap    animal    therapeutic   

Project "HEXKIN" data sheet

The following table provides information about the project.

Coordinator
EXOGENUS THERAPEUTICS SA 

Organization address
address: PARQUE BIOCANT NUCLEO 04 LOTE 2
city: CANTANHEDE
postcode: 3060 197
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Project website http://www.exogenus-t.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EXOGENUS THERAPEUTICS SA PT (CANTANHEDE) coordinator 50˙000.00

Map

 Project objective

Currently, there are about 50 million reported cases globally of patients suffering from hard-to-close wounds, which constitute a severe cost burden to the global healthcare systems. Considering that for these patients up to 70% of the wounds may not heal with standard care, there is a high demand for new solutions with better efficacy for the treatment of wounds. Cell therapies have emerged as promising therapeutic strategies to solve the problem of chronic wounds, but the limited engraftment and survival of the cells have restricted their efficacy in late stages of human trials. Exogenus is a spin-out company dedicated to develop a new therapeutic tool for the treatment of chronic wounds – Exo-Wound - which the company now seeks to clinically validate for diabetic ulcers. Exo-Wound is based on factors secreted by Umbilical Cord Blood (UCB) cells which accelerate the healing of skin wounds through promotion of vascularisation and stimulation of skin growth. Results from the animal models reveal important improvements in the healing capacity, treatment duration and biocompatibility when compared to competition. Nevertheless, in order to secure swift product development and successful commercialisation Exogenus is in need of partnerships and capital to overcome the classic ”Valley of death” gap. We believe the SME instrument is the ideal funding vehicle for us to establish Exo-Wound clinical validation and undertake the necessary activities to demonstrate safety and efficacy of the product in humans, and eventually achieve successful, global commercialization. The project will contribute to place Exogenus in a competitive position within the advanced wound care market and assist Europe in maintaining its competitive position in the fast growing segment of active therapies. The accomplishment of the project objectives will lead to a significant business opportunity for Exogenus, and generate revenues of around €30 million, five years after market entrance.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HEXKIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HEXKIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More  

SBR (2020)

SMART BONE REGENERATION

Read More